Market Insider

Midday movers: Tesla Motors, Ralph Lauren, Microsoft & more

Take a look at some of Wednesday's midday movers:

Tesla Motors fell sharply after reporting earnings that disappointed investors. It delivered 5,500 Model S cars in the third quarter, below what some analysts had expected.

Ralph Lauren rose after the upscale clothing brand hiked its full-year sales forecast on expectations of a strong holiday season. It also raised its dividend.

Barracuda Networks had a strong market debut after the data-storage company priced 4.1 million shares at $18.

Halliburton gained after the provider of services to oil-and-gas drillers announced a 20 percent hike in its quarterly dividend to 15 cents a share.

Microsoft hit a 12-year-high. Nomura analyst Rick Sherlund said the software maker's earnings could reach $3.80 a share next year, versus the consensus estimate of $2.67. He raised his price target to $45 a share and kept a buy rating on its stock.

Ruby Tuesday gained after the restaurant chain's CEO disclosed purchasing 100,000 shares on Monday at $5.88 each.

Curis fell after the FDA put a partial hold on its experimental cancer drug following the death of a patient who had liver failure.

AMR fell after JPMorgan downgraded the stock to neutral from overweight, saying news that its merger chances with US Airways have increased is already priced in.

Vivus declined after BofA/Merrill Lynch downgraded the obesity-drug company to neutral from buy.

AngloGold Ashanti rose after posting strong third-quarter earnings.

Red Robin Gourmet Burgers fell after BofA/Merrill Lynch downgraded the casual-dining chain to underperform from neutral.

Activism Blizzard rose after the video-game publisher said it sold more than $1 billion worth of its latest 'Call of Duty' title into retail stores on the game's first available day.

Abiomed rose after the maker of heart devices reported better-than-expected second-quarter earnings and revenue.

Auxilium Pharmaceuticals rose after its third-quarter profit beat street forecasts, boosted by strong drug sales from a recently acquired company.

(

—By CNBC's Rich Fisherman.

Questions? Comments? Email us at